Search Results

Octave ® Bioscience, Inc. today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.

Octave® Bioscience, Inc. announced the appointment of two key executives, Jeron Evans as Chief Revenue Officer and Debbie Ledet as Chief Access Officer.

Octave ® Bioscience, Inc. Announces Chairman of the Board, CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for its Precision Care Solution.

Octave Bioscience today announced the closing of a $30M extension to its Series B funding round.

Octave® Bioscience, Inc. announced new data shared in nine poster presentations at MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS Meeting.

Octave® Bioscience, Inc. announced that it has been awarded a $10M grant from The Michael J. Fox Foundation for Parkinson’s Research.

Octave® Bioscience, Inc., a leading precision care company focused on delivering a new standard of care for multiple sclerosis (MS) and other neurodegenerative diseases, today announced the publication of the successful clinical validation of the Octave® Multiple Sclerosis Disease Activity (MSDA) Test in the peer-reviewed journal Clinical Immunology.

Octave® Bioscience, Inc. was honored in Fast Company’s Innovation by Design Awards for 2023 in the Health category.

Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced today that it plans to conduct an observational, real-world study with Biogen (Nasdaq: BIIB) as the sponsor.

Octave announced the presentation of nine abstracts at the Americas Committee for Treatment and Research in Multiple Sclerosis Conference 2023.